Mario Lemieux Foundation

Goals
- Open two new playrooms in 2024; provide maintenance on existing playrooms in 2023.
- Increase awareness of our programs in both pediatric lymphomas and blood cancers treatment and patient care and expand pediatric oncology research at the newly established research institute
-Open Lemieux Immunotherapy Center in 2024

- Continue following the established MLF Strategic Plan as updated in November 2022
-Continue following the Playroom specifics of the plan and raise the appropriate dollars for these goals to open more playrooms
- Continued support of our existing programs in both pediatric lymphomas and blood cancers treatment as well as patient care

We feel confident that we will meet these goals given our proven track record. Our Board and staff are fully committed to the success of the organization.

The Mario Lemieux Foundation is consistently reaching those in need. With 43 Austin's Playrooms, we estimate that we have reached over 2 million children and families through our rooms. This is an exciting benchmark and we will continue to reach more kids to make their hospital experience a positive one.

The newly opened Mario Lemieux Pediatric Cancer Institute will prove cutting-edge care and clinical trials for patients. The Institute will also ensure that the most talented researchers are recruited and stay in Pittsburgh to support this project.

The Lemieux Innovation Fund at AHN's Cardiac Institute is making incredible strides in afib research. We expect this project to continue to help more individuals with new clinical breakthroughs.

Additionally, in our Lymphoma Center for Children and Young Adults, our researchers and clinicians are the best in their field, and we feel confident they are making big strides in quality treatments. They recently found a tumor suppressor and that is a huge find in this field. Their discovery led to more NIH funding and will potentially change the way lymphoma patients are treated. We expect our pediatric oncology program to grow.

Finally, with our Center for Blood Cancers, we are treating over 30,000 patients annually in the state-of-the art outpatient center that did not exist 30 years ago when Mario went through his experience with Hodgkin's disease. we expect those patient numbers to grow. Our Center is unique as it uses the patient-centric model which brings coordinated care and services to the patient, eliminating wait times and multiple stops during their visit. Our continued goal there is to make it as easy and comfortable for the patient as possible. Additionally, the opening of the Mario Lemieux Immunotherapy Center in 2024 (projected), will expand our reach to patients by seeing not only patients with blood cancers, but also solid tumor cancers.